Podcast: Weigh Uncertainty Of EAP Process Before Diving In, Experts Say
This article was originally published in The Gray Sheet
Executive Summary
Despite some industry enthusiasm for FDA's Expedited Access Pathway, experts with King and Spalding urge companies to take into consideration the uncertainties associated with the new pathway compared to long experience with the PMA process, and the costs associated with EAP's postmarket requirements.